Effect of resveratrol on fat mobilization

Annals of the New York Academy of Sciences

Volumn 1215, Issue 1, 2011, Pages 40-47

  Baile, Clifton A ^a   Yang, Jeong Yeh ^a   Rayalam, Srujana ^a   Hartzell, Diane L ^a   Lai, Ching Yi ^a   Andersen, Charlotte ^b   Della Fera, Mary Anne ^a  

^a UNIVERSITY OF GEORGIA   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Adipocytes; Natural products; Obesity; Osteoporosis; Phytochemicals; Rodents

Indexed keywords

ANTIOBESITY AGENT; FAT; GENISTEIN; NATURAL PRODUCT; QUERCETIN; RESVERATROL; VITAMIN D;

ADIPOGENESIS; ADIPOSE TISSUE; ARTICLE; BODY FAT; CELL CYCLE; CELL PROLIFERATION; DIET SUPPLEMENTATION; DNA TEMPLATE; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LIPID DIET; LIPOGENESIS; LIPOLYSIS; MONOTHERAPY; NONHUMAN; OBESITY; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; PROADIPOCYTE; WEIGHT GAIN;

MUS; RATTUS; RODENTIA;

EID: 78851469588     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05845.x     Document Type: Article

References (62)

1. World Health Organization. World Health Statistics. 2009. Available at: Accessed July 1, 2010.
2. Visscher, T.L. & J.C. Seidell 2001. The public health impact of obesity. Annu. Rev. Public Health 22: 355-375.
3. Cooper, C. 1999. Epidemiology of osteoporosis. Osteoporos Int. 9(Suppl 2): S2-S8.
4. de Simone, G. & G. D'Addeo 2008. Sibutramine: balancing weight loss benefit and possible cardiovascular risk. Nutr. Metab. Cardiovasc. Dis. 18: 337-341.
5. Gennari, L., D. Merlotti, F. Valleggi & R. Nuti 2009. Ospemifene use in postmenopausal women. Expert Opin. Investig. Drugs 18: 839-849.
6. Post, T.M., S.C. Cremers, T. Kerbusch & M. Danhof 2010. Bone physiology, disease and treatment: towards disease system analysis in osteoporosis. Clin. Pharmacokinet 49: 89-118.
7. Kessler, R.C., R.B. Davis, D.F. Foster, et al 2001. Long-term trends in the use of complementary and alternative medical therapies in the United States. Ann. Intern. Med. 135: 262-268.
8. Mayer, M.A., C. Hocht, A. Puyo & C.A. Taira 2009. Recent advances in obesity pharmacotherapy. Curr. Clin. Pharmacol. 4: 53-61.
9. Calixto, J.B., M.M. Campos, M.F. Otuki & A.R. Santos 2004. Anti-inflammatory compounds of plant origin. Part II. modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med. 70: 93-103.
10. Flier, J.S. 1995. The adipocyte: storage depot or node on the energy information superhighway Cell 80: 15-18.
11. Gregoire, F.M. 2001. Adipocyte differentiation: from fibroblast to endocrine cell. Exp. Biol. Med. (Maywood) 226: 997-1002.
12. Wang, Y., K.A. Kim, J.H. Kim & H.S. Sul 2006. Pref-1, a preadipocyte secreted factor that inhibits adipogenesis. J. Nutr. 136: 2953-2956.
13. Umek, R.M., A.D. Friedman & S.L. McKnight 1991. CCAAT-enhancer binding protein: a component of a differentiation switch. Science 251: 288-292.
14. Pairault, J. & H. Green 1979. A study of the adipose conversion of suspended 3T3 cells by using glycerophosphate dehydrogenase as differentiation marker. Proc. Natl. Acad. Sci. USA 76: 5138-5142.
15. Arichi, H., Y. Kimura, H. Okuda, et al 1982. Effects of stilbene components of the roots of Polygonum cuspidatum Sieb. et Zucc. on lipid metabolism. Chem. Pharm. Bull. (Tokyo). 30: 1766-1770.
16. Picard, F., M. Kurtev, N. Chung, et al 2004. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429: 771-776.
17. Rayalam, S., J.Y. Yang, S. Ambati, et al 2008. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytotherapy Res. 22: 1367-1371.
18. Szkudelska, K., L. Nogowski & T. Szkudelski 2009. Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J. Steroid Biochem. Mol. Biol. 113: 17-24.
19. Fischer-Posovszky, P., V. Kukulus, D. Tews, et al 2010. Resveratrol regulates human adipocyte number and function in a Sirt1-dependent manner. Am. J. Clin. Nutr. 92: 5-15.
20. Mader, I., M. Wabitsch, K.M. Debatin, et al 2010. Identification of a novel proapoptotic function of resveratrol in fat cells: SIRT1-independent sensitization to TRAIL-induced apoptosis. Faseb J. 24: 1997-2009.
21. Ferry-Dumazet, H., O. Garnier, M. Mamani-Matsuda, et al 2002. Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis 23: 1327-1333.
22. Liang, Y.C., S.H. Tsai, L. Chen, et al 2003. Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem. Pharmacol. 65: 1053-1060.
23. Lazar, M.A. 2002. Becoming fat. Genes Dev. 16: 1-5.
24. Kim, J.B., H.M. Wright, M. Wright & B.M. Spiegelman 1998. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc. Natl. Acad. Sci. USA 95: 4333-4337.
25. Auwerx, J., P. Leroy & K. Schoonjans 1992. Lipoprotein lipase: recent contributions from molecular biology. Crit. Rev. Clin. Lab. Sci. 29: 243-268.
26. Sztalryd, C., M.C. Komaromy & F.B. Kraemer 1995. Overexpression of hormone-sensitive lipase prevents triglyceride accumulation in adipocytes. J. Clin. Invest. 95: 2652-2661.
27. Zhang, J. 2006. Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem. J. 397: 519-527.
28. Gerhart-Hines, Z., J.T. Rodgers, O. Bare, et al 2007. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. Embo J. 26: 1913-1923.
29. Shi, T., F. Wang, E. Stieren & Q. Tong 2005. SIRT3, a mitochondrial sirtuin deacetylase, regulates mitochondrial function and thermogenesis in brown adipocytes. J. Biol. Chem. 280: 13560-13567.
30. Mingrone, G., M. Manco, M. Calvani, et al 2005. Could the low level of expression of the gene encoding skeletal muscle mitofusin-2 account for the metabolic inflexibility of obesity Diabetologia 48: 2108-2114.
31. Zorzano, A., D. Bach, S. Pich & M. Palacin 2004. [Role of novel mitochondrial proteins in energy balance]. Rev. Med. Univ. Navarra. 48: 30-35.
32. Gonzales, A.M. & R.A. Orlando 2008. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr. Metab. (Lond). 5: 17-30.
33. Ahn, J., H. Lee, S. Kim & T. Ha 2007. Resveratrol inhibits TNF-alpha-induced changes of adipokines in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 364: 972-977.
34. Kang, L., W. Heng, A. Yuan, et al 2010. Resveratrol modulates adipokine expression and improves insulin sensitivity in adipocytes: Relative to inhibition of inflammatory responses. Biochimie 92: 789-796.
35. Olholm, J., S.K. Paulsen, K.B. Cullberg, et al 2010. Anti-inflammatory effect of resveratrol on adipokine expression and secretion in human adipose tissue explants. Int. J. Obes (Lond). 34: 1546-1553.
36. Lagouge, M., C. Argmann, Z. Gerhart-Hines, et al 2006. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127: 1109-1122.
37. Howitz, K.T., K.J. Bitterman, H.Y. Cohen, et al 2003. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196.
38. Kaeberlein, M., T. McDonagh, B. Heltweg, et al 2005. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280: 17038-17045.
39. Um, J.H., S.J. Park, H. Kang, et al 2010. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59: 554-563.
40. Ambati, S., J.Y. Yang, S. Rayalam, et al 2009. Ajoene exerts potent effects in 3T3-L1 adipocytes by inhibiting adipogenesis and inducing apoptosis. Phytother. Res. 23: 513-518.
41. Lai, C.Y., J.Y. Yang, S. Rayalam, et al 2010. Preventing Bone Loss and Weight Gain with Combinations of Vitamin D and Phytochemicals. J. Med. Food In press.
42. Park, H.J., J.Y. Yang, S. Ambati, et al 2008. Combined Effects of Genistein, Quercetin and Resveratrol in Human and 3T3-L1 Adipocytes. J. Med. Food 11: 773-783.
43. Rayalam, S., M.A. Della-Fera, S. Ambati, et al 2007. Enhanced effects of guggulsterone plus 1, 25(OH)2D3 on 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 364: 450-456.
44. Rayalam, S., M.A. Della-Fera, J.Y. Yang, et al 2007. Resveratrol potentiates genistein's anti-adipogenic and pro-apoptotic effects in 3T3-L1 adipocytes. J. Nutr. 137: 2668-2673.
45. Rayalam, S., J.Y. Yang, M.A. Della-Fera, et al 2009. Anti-obesity effects of xanthohumol plus guggulsterone in 3T3-L1 adipocytes. J. Med. Food 12: 846-853.
46. Yang, J.Y., M.A. Della-Fera, S. Rayalam, et al 2008. Enhanced pro-apoptotic and anti-adipogenic effects of genistein plus guggulsterone in 3T3-L1 adipocytes. Biofactors 30: 159-169.
47. Yang, J.Y., M.A. Della-Fera, S. Rayalam, et al 2008. Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci. 82: 1032-1039.
48. Yang, J.Y., M.A. Della-Fera, S. Rayalam & C.A. Baile 2008. Enhanced effects of xanthohumol plus honokiol on apoptosis and lipolysis in 3T3-L1 adipocytes. Obesity (Silver Spring) 16: 1232-1238.
49. Mizutani, K., K. Ikeda, Y. Kawai & Y. Yamori 1998. Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem. Biophys. Res. Commun. 253: 859-863.
50. Dai, Z., Y. Li, L.D. Quarles, et al 2007. Resveratrol enhances proliferation and osteoblastic differentiation in human mesenchymal stem cells via ER-dependent ERK1/2 activation. Phytomedicine 14: 806-814.
51. Backesjo, C.M., Y. Li, U. Lindgren & L.A. Haldosen 2009. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. Cells Tissues Organs 189: 93-97.
52. Kao, C.L., L.K. Tai, S.H. Chiou, et al 2009. Resveratrol promotes osteogenic differentiation and protects against dexamethasone damage in murine induced pluripotent stem cells. Stem. Cells Dev. 19: 247-258.
53. Liu, Z.P., W.X. Li, B. Yu, et al 2005. Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. J. Med. Food 8: 14-19.
54. Habold, C., I. Momken, A. Ouadi, et al 2010. Effect of prior treatment with resveratrol on density and structure of rat long bones under tail-suspension. J. Bone Miner. Metab. In press.
55. Mizutani, K., K. Ikeda, Y. Kawai & Y. Yamori 2000. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol (Tokyo) 46: 78-83.
56. Sakaguchi, K., I. Morita & S. Murota 2000. Relationship between the ability to support differentiation of osteoclast-like cells and adipogenesis in murine stromal cells derived from bone marrow. Prostaglandins Leukot Essent Fatty Acids 62: 319-327.
57. Rosen, C.J. & M.L. Bouxsein 2006. Mechanisms of disease: is osteoporosis the obesity of bone Nat. Clin. Pract. Rheumatol. 2: 35-43.
58. Aziz, M.H., M. Nihal, V.X. Fu, et al 2006. Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-kinase/Akt pathway and Bcl-2 family proteins. Mol. Cancer Ther. 5: 1335-1341.
59. Canto, C. & J. Auwerx 2009. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 20: 98-105.
60. Fullerton, M.D. & G.R. Steinberg 2010. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes 59: 551-553.
61. Szkudelska, K. & T. Szkudelski 2010. Resveratrol, obesity and diabetes. Eur. J. Pharmacol. 635: 1-8.
62. Backesjo, C.M., Y. Li, U. Lindgren & L.A. Haldosen 2006. Activation of Sirt1 decreases adipocyte formation during osteoblast differentiation of mesenchymal stem cells. J. Bone Miner. Res. 21: 993-1002.